No Data
No Data
AnaptysBio Price Target Raised to $69.00/Share From $29.00 by JP Morgan
AnaptysBio Price Target Raised to $69.00/Share From $29.00 by JP
AnaptysBio Raised to Overweight From Neutral by JP Morgan
AnaptysBio Raised to Overweight From Neutral by JP
AnaptysBio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 96.86% JP Morgan $29 → $69 Upgrades Neutral → Overweight 05/10/2024 -3% Wedbush → $34
Top Premarket Gainers
Serve Robotics (SERV) shares surged 75% in recent Friday premarket activity, extending Thursday's rally.60 Degrees Pharmaceuticals (SXTP) shares were 60% higher, adding to Thursday's 5.2% gain.
JPMorgan Upgrades AnaptysBio to Overweight From Neutral, Adjusts Price Target to $69 From $29
AnaptysBio (ANAB) has an average outperform rating and a price target range of $20 to $80, according to analysts polled by Capital IQ.Price: 37.00, Change: +2.55, Percent Change: +7.40
J.P. Morgan Upgrades AnaptysBio(ANAB.US) to Buy Rating, Raises Target Price to $69
J.P. Morgan analyst Anupam Rama upgrades $AnaptysBio(ANAB.US)$ to a buy rating, and adjusts the target price from $29 to $69.According to TipRanks data, the analyst has a success rate of 48.7% and a
No Data